|

ACP-211 Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Pipeline

Phase 2: 1

Top Sponsors

  • ACADIA Pharmaceuticals Inc.1

Indications

  • Depressive Disorder, Treatment-Resistant1
  • Major Depressive Disorder (MDD)1
  • Depression1

Birmingham, Alabama1 trial

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

University of Alabama at Birmingham

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.